This site is intended for health professionals only

At the heart of general practice since 1960

pulse june2020 80x101px
Read the latest issue online

The waiting game

'NICE's asthma guideline is not fit for purpose'

Dr Dermot Ryan on NICE's new asthma guideline

Dr Dermot Ryan 330x330px

Dr Dermot Ryan 330x330px

It is really important that patients with asthma receive a proper diagnosis but the overconcentration on one parameter – in this case FeNO – is neither here nor there. Most GPs don’t have access to FeNO and most CCGs don’t have the funds or the know-how to invest in it.

Furthermore, many adults with asthma don’t have a phenotype that leads to elevated FeNO results, so a negative FeNO doesn’t mean they haven’t got asthma. I think the guideline is setting GPs up for failure because there isn’t access to these resources.

The recommendation to add an LTRA to inhaled corticosteroid therapy is foolish on many levels - European colleagues will be laughing and the Scots to whom this doesn’t apply will look down their noses in scorn at this outlandish proposal. In the best trials, there are only a few people who respond well to LTRAs.

For the rest though, they’re coming back 4-8 weeks after being given the LTRA, which is time during which they have symptoms, they may have an exacerbation, the surgery has to provide another appointment and the patient is following a confusing mixed regimen.

This is being done purely for cost minimisation – for an organisation that purports to uphold clinical excellence, this is not clinical excellence. This should be resisted and it won’t save money. It’s not for no reason that guidelines elsewhere in the world recommend a LABA as the first add-on to inhaled corticosteroid.

Really this guideline is not fit for purpose.

Dr Dermot Ryan is president of the Respiratory Effectiveness Group and a GP in Loughborough


Rate this article  (5 average user rating)

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Readers' comments (1)

  • David Banner

    Relax, no GP worth his salt pays the slightest attention to NICE any more. They shot their credibility bolt with their d(r)aft diabetes guidance, now their asthma claptrap is making them a laughing stock.

    We know FENO's a no go.

    Unsuitable or offensive? Report this comment

Have your say